Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Integer Holdings Corporation
ITGR
NYSE·Healthcare·Medical - Devices·Mkt cap $3.2B
$95.20
▲ +0.67%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$62.00 - $122.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 22.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established relationships with multi-national OEM customers providing recurring revenue and high switching costs
- Vertically integrated manufacturing capabilities across multiple geographies enabling cost efficiency and supply chain resilience
- Specialized expertise in complex medical device manufacturing including miniaturization, biocompatibility, and regulatory compliance
- Diversified product portfolio across multiple therapeutic areas reducing customer concentration risk
- Decades of operational history (founded 1970) with deep industry knowledge and manufacturing excellence
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Steady revenue growth (8% YoY)
Value
Fairly valued vs Medical Devices peers
Momentum
Strong
+8.9% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying ITGR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 22, 2026
APR 30, 2026
Reported EPS of $1.20 vs $1.21 consensus (-0.8% surprise). Revenue of $439.6M vs $426.5M expected (+3.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-0.8%
Next: Apr 22, 2026
Revenue trend · last 8Q
—
—
+11%
+7%
+11%
+8%
+5%
+1%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$427.9M
$431.4M
$449.5M
$437.4M
$476.5M
$467.7M
$472.1M
$439.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
3.8%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$115.00
▲ +20.8% vs $95.20
Latest: Citi · May 28, 2026
1 analyst covering